United Kingdom

People: AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

24 May 2019
Change (% chg)

$0.32 (+1.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Gold, Mark 

Dr. Mark Stephen Gold, M.D. is an Independent Director of AxoGen, Inc., since September 30, 2011. From 1990 until his retirement in June 2014, Dr. Gold was a Professor at the University of Florida College of Medicine’s McKnight Brain Institute and was recognized as a Distinguished Professor and Eminent Scholar and was Chairman of the Department of Psychiatry. He has also been recognized as the 17th University of Florida Distinguished Alumni Professor. Dr. Gold taught neuroanatomy and medical neuroscience for four decades and has been a pioneer in translational neuroscience research. He has been a consultant and senior advisor to banks and private equity and venture capital firms on medical devices, pharmaceuticals and health care services throughout his career. Dr. Gold was also a Founding Director of the Somerset Valley Bank and Somerset Valley Financial (NASDAQ: SVBF) from 1991 to 1999 which was sold to Fulton Financial Corporation. Dr. Gold was a Founding Director and has served on the board of directors of Viewray, Inc. (NASDAQ:VRAY) since the company’s formation in September 2011. Dr. Gold is a Director of The Magstim Company Ltd., a United Kingdom based global leader in brain stimulation, nerve modulation, and intraoperative nerve monitoring and Viewray, a public commercial stage MR-Guided Radiotherapy company specializing in Cancer treatment. Dr. Gold is also Chairman of the Scientific Advisory Board of RiverMendHealth.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 64,749
Long-Term Incentive Plans, USD --
All Other, USD 55,000
Fiscal Year Total, USD 119,749

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --